Publication:
Association between Metformin and a Lower Risk of Age-Related Macular Degeneration in Patients with Type 2 Diabetes

Simple item page
cris.lastimport.scopus2026-03-05T16:02:04Z
dc.creatorChen, Yu-Yen
dc.creatorShen, Ying-Cheng
dc.creatorLai, Yun-Ju
dc.creatorWang, Chun-Yuan
dc.creatorLin, Keng-Hung
dc.creatorFeng, Shih-Chao
dc.creatorLiang, Chiao-Ying
dc.creatorWei, Li-Chen
dc.creatorChou, Pesus
dc.date2019-10-31
dc.date.accessioned2021-11-02T06:50:56Z
dc.date.accessioned2025-07-28T15:04:20Z
dc.date.available2021-11-02T06:50:56Z
dc.date.issued2021-11-02T06:50:56Z
dc.description.abstractPurpose. This population-based, retrospective cohort study was to investigate whether metformin is associated with a lower risk of subsequent age-related macular degeneration (AMD) in patients with type 2 diabetes. Methods. Using the Taiwan National Health Insurance Research Database from 2001 to 2013, 68205 subjects with type 2 diabetes were enrolled in the study cohort. Among them, 45524 were metformin users and 22681 were nonusers. The metformin and nonmetformin groups were followed until the end of 2013. Cox regression analyses were used to estimate hazard ratios (HRs) for AMD development associated with metformin use. Confounders included for adjustment were age, sex, and comorbidities (hypertension, hyperlipidemia, coronary artery disease, obesity, diabetic retinopathy, chronic kidney disease, and insulin treatment). Furthermore, propensity score (PS) matching method was used to choose the matched sample, and PS-adjusted Cox regression was performed. Finally, how HRs changed according to metformin treatment duration and dose was also evaluated in the metformin group. Results. After adjusting for confounders, the metformin group had a significantly lower risk of AMD (adjusted HR=0.54; 95% confidence interval [CI], 0.50-0.58). In the PS-matched sample, the significance remained (adjusted HR=0.57; 95% CI, 0.52-0.63). In the metformin group, the adjusted HRs for the second (1.5-4 years) and third (>= 4 years) tertiles of metformin treatment duration were 0.52 and 0.14, respectively, compared with the first tertile (<1.5 years). We also found significant trends of lower HRs (all p-value for trend <0.05) with increasing total and average doses. Conclusions. Among patients with type 2 diabetes, those who use metformin are at a significantly lower risk of developing AMD relative to individuals who do not use metformin. Also, the trend of a significantly lower AMD risk was found with a higher dose of metformin.
dc.format.extent115 bytes
dc.format.mimetypetext/html
dc.identifier.doi10.1155/2019/1649156
dc.identifier.issn2090-004X
dc.identifier.urihttps://ir.ntus.edu.tw/handle/987654321/65581
dc.languageen_US
dc.publisherLondon:HINDAWI
dc.relationJOURNAL OF OPHTHALMOLOGY, 2019
dc.subjectOXIDATIVE STRESS
dc.subjectCHOROIDAL NEOVASCULARIZATION
dc.subjectGLUCOSE CONTROL
dc.subjectCANCER-RISK
dc.subjectINFLAMMATION
dc.subjectINHIBITION
dc.subjectDISEASE
dc.subjectMARKERS
dc.subjectIMPACT
dc.subjectRPE
dc.titleAssociation between Metformin and a Lower Risk of Age-Related Macular Degeneration in Patients with Type 2 Diabetes
dc.typearticle
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
index.html
Size:
115 B
Format:
Hypertext Markup Language
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
702 B
Format:
Plain Text
Description:
Download

Collections

期刊論文